Inclusion Criteria:  Persistent or recurrent EOC that meets the following criteria: Histologically confirmed non-high-grade serous, non-high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (i.e., low-grade serous ovarian carcinoma, clear cell carcinoma, mucinous carcinoma, carcinosarcoma, undifferentiated carcinoma, seromucinous carcinoma, malignant Brenner tumors, Grades 1 or 2 endometrioid carcinoma, or small cell carcinoma of the ovary-hypercalcemic type); Disease that is not amenable to curative surgery Measurable disease (at least one target lesion) according to RECIST v1.1 Previous treatment with one to four lines of therapy, at least one of which was platinum-based Platinum-resistant disease (disease progression within 6 months of last platinum therapy) Submission of a representative tumor specimen that is suitable for central molecular analysis (for mandatory NGS testing to determine treatment arm assignment) Submission of stained pathology slides, along with the associated pathology report (for central pathology review) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Adequate hematologic and end-organ function Female of childbearing potential must be willing to comply with adequate contraception In addition to the general inclusion criteria above, participants must meet all of the arm-specific inclusion criteria for the respective arm  General Exclusion Criteria:  Pregnant or breastfeeding, or intending to become pregnant or breastfeed during the study Primary platinum-refractory disease, defined as progression during or within 4 weeks after the last dose of the first-line platinum treatment Histologic diagnosis of high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer Current diagnosis of solely borderline epithelial ovarian tumor Current diagnosis of non-epithelial ovarian tumors Current diagnosis of synchronous primary endometrial cancer Prior history of primary endometrial cancer, with the following exception: a prior diagnosis of primary endometrial cancer is permitted if it meets all of the following conditions: Stage IA, no lymphovascular invasion, International Federation of Gynecology and Obstetrics Grade 1 or 2, not a high-grade subtype. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures Symptomatic, untreated, or actively progressing CNS metastases Severe infection within 4 weeks prior to initiation of study treatment Treatment with chemotherapy, radiotherapy, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, or investigational therapy within 28 days prior to initiation of study treatment Treatment with hormonal therapy within 14 days prior to initiation of study treatment In addition to the general exclusion criteria above, participants must meet all of the arm-specific exclusion criteria for the respective arm